Riskpilot← Back to searchSign inGet full accesskg-pharma AB
ABActiveOrg 5592857501Björnholmsvägen 4Manufacture of machinery for food, beverage and tobacco processing · NACE 2893Est. 20203 employees
Revenue 2025
SEK 19,4M
+1% vs 2024
EBITDA margin
-0.3%
-105% vs 2024
Equity ratio
43.2%
Financial strength
Net profit 2025
SEK 86K
-89% vs 2024
| Revenue | SEK 19,4M | +1% |
| EBITDA | SEK -57K | -105% |
| Net profit | SEK 86K | -89% |
| Total assets | SEK 4,4M | -52% |
| Equity | SEK 1,9M | -4% |
| Employees | 3 | — |
Legal name
kg-pharma AB
Org number
5592857501
Legal form
Aktiebolag
NACE code
2893 · Manufacture of machinery for food, beverage and tobacco processing
Founded
26 november 2020
Share capital
SEK 25 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget bedriver verksamhet inom global handel med farmaceutiska maskiner.
Address
Björnholmsvägen 4
Email
ingo.krause@kg-pharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12 294 | 17 456 | 22 693 | 19 136 | 19 394 |
| Staff expenses | — | −1 450 | −1 555 | — | −1 953 |
| EBITDA | 948 | 388 | 1 164 | 1 058 | −57 |
| Depreciation & amort. | −38 | −164 | −186 | −69 | −54 |
| EBIT | 910 | 225 | 978 | 989 | −112 |
| Net financials | −4 | −0 | 4 | 25 | 5 |
| Profit before tax | 678 | 224 | 982 | 1 013 | 121 |
| Tax | −146 | −50 | −206 | −217 | −35 |
| Net profit | 532 | 174 | 776 | 796 | 86 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 331 | 4 899 | 4 630 | 9 130 | 4 414 |
| Equity | 557 | 731 | 1 507 | 1 992 | 1 909 |
| Long-term debt | 429 | 142 | 0 | 0 | — |
| Short-term debt | 2 118 | 3 798 | 2 895 | 6 911 | 2 505 |
| Total debt | 2 547 | 3 940 | 2 895 | 6 911 | 2 505 |
EBITDA margin
-0.3%
This company
15.8%
Market median
-102% vs market
20212025
Equity ratio
43.2%
This company
38.2%
Market median
+13% vs market
20212025
Return on equity
4.5%
This company
18.4%
Market median
-76% vs market
20212025
Net profit margin
0.4%
This company
8.1%
Market median
-95% vs market
20212025
Asset turnover
4.39×
This company
1.12×
Market median
+292% vs market
20212025
Debt / equity
1.31×
This company
0.62×
Market median
-111% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TS Authorized Recipient of Service | Authorized Recipient of Service | 2021 | — | — |
EA Audit | Audit | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of kg-pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Taave Sööt Vahermägi | Authorized Recipient of Service | 0 companies |
| Erdinc Aron Cicek | Audit | 0 companies |
| Nataliia Krause | Deputy Board Member | 0 companies |
| Kristyna Novakova | Deputy Board Member | 0 companies |
| Ragnar Everest | Board of Directors | 0 companies |
| Ingo Krause | Board of Directors | 0 companies |
| Ingo Krause | Board of Directors | 0 companies |